Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Picks of the quarter -- Ignore unavailable to you. Want to Upgrade?

To: Elroy who wrote (12414)	1/5/2012 11:24:14 PM
From: Cogito	Respond to of 20435

>>Hold on there, the fat lady hasn't sung yet....<< Hey, I said it was early. You want to cover the action for anybody who wants to bet against him?

To: Elroy who wrote (12414)	1/8/2012 12:12:51 AM
From: Sr K	Respond to of 20435

Look what can happen in 1 day. DEALS & DEAL MAKERS \| JANUARY 8, 2012 Bristol-Myers to Buy Inhibitex for $2.5 Billion By JONATHAN D. ROCKOFF, ANUPREETA DAS and GINA CHON Drug maker Bristol-Myers Squibb Co. said it is buying hepatitis C drug developer Inhibitex Inc. for about $2.5 billion, marking the latest deal in the growing business of treating the potentially fatal virus. The all-cash deal for $26 a share would pay Inhibitex a whopping 163% premium to its Friday closing price. Inhibitex makes drugs for infectious diseases, including bacterial and viral infections such as shingles and chronic hepatitis C. Shares of Inhibitex closed Friday at $9.87 a share, giving the company a market capitalization of roughly $773 million.